News
TYRA
7.59
-1.09%
-0.08
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 3d ago
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended March 31, 2...
PR Newswire · 05/05 20:05
BRIEF-Tyra Biosciences Posts Q4 Net Loss Of $9.9 Million
reuters.com · 03/03 21:39
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter and year ended De...
PR Newswire · 03/03 21:05
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be participating in a co...
PR Newswire · 02/22 21:05
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Cor...
GuruFocus.com · 12/21/2021 23:38
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 12/15/2021 14:29
Beware of These 3 Recent IPOs That are Overvalued
StockNews.com · 11/11/2021 15:56
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will participate in a firesid...
PR Newswire · 11/10/2021 21:05
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended September 3...
PR Newswire · 11/03/2021 20:05
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator f...
Benzinga · 09/22/2021 12:22
LIVE MARKETS-U.S. stocks tumble as S&P 500 suffers 50-day fumble
reuters.com · 09/17/2021 20:30
LIVE MARKETS-Investors try to sort out supply shortages
reuters.com · 09/17/2021 17:43
LIVE MARKETS-Keeping the equities weight on
reuters.com · 09/17/2021 16:40
LIVE MARKETS-That's three straight weeks in the red for Europe
reuters.com · 09/17/2021 15:57
Tyra Announces Pricing of Upsized Initial Public Offering
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the pricing of its upsized initial public offering...
PR Newswire · 09/15/2021 01:00
More
Webull provides a variety of real-time TYRA stock news. You can receive the latest news about Tyra Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TYRA
Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.